Drug Target Review

OCTOBER 2, 2024

While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. As with all CGTs, safety concerns, particularly related to immune responses and long-term effects, are crucial in cardiology. Allogeneic cell therapies must avoid immune rejection.

Therapies 52

Therapies Disease Engineering RNA 52

Broad Institute

OCTOBER 11, 2023

By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118